Publicaciones en colaboración con investigadores/as de Mutua de Terrassa (9)

2024

  1. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

2023

  1. Automatic Segmentation and Quantification of Nigrosome-1 Neuromelanin and Iron in MRI: A Candidate Biomarker for Parkinson's Disease

    Journal of Magnetic Resonance Imaging

  2. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma

    Blood, Vol. 142, Núm. 18, pp. 1518-1528

2022

  1. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

2020

  1. Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study

    Journal of Neuro-Oncology, Vol. 148, Núm. 3, pp. 545-554

2019

  1. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

  2. Dynamic atlas-based segmentation and quantification of neuromelanin-rich brainstem structures in Parkinson disease

    IEEE Transactions on Medical Imaging, Vol. 38, Núm. 3, pp. 813-823

  3. Globular glial tauopathy caused by MAPT P301T mutation: clinical and neuropathological findings

    Journal of Neurology, Vol. 266, Núm. 10, pp. 2396-2405

2015

  1. Automated Neuromelanin Imaging as a Diagnostic Biomarker for Parkinson's Disease

    Movement Disorders, Vol. 30, Núm. 7, pp. 945-952